Tailoring Hemophilia Prophylaxis Therapy

Slides:

Advertisements

Similar presentations

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Upfront Combination Therapy vs Step-Up Approach for PAH:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

PrEP: A Case-by-Case Approach

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Why Gene Therapy for Hemophilia?

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Perspectives on Triple-Negative Breast Cancer

Prophylaxis Considerations for Teenagers and Young Adults With Severe Hemophilia.

Tailoring Statin Therapy in Women

Case 53-year-old Black Man

Progression After Cancer Immunotherapy in Advanced NSCLC

Hemophilia Updates: Incorporating New Concepts Into Practice

Extended Half-life Factor Products in the Management of Hemophilia

Individualizing Prophylaxis in Hemophilia

Hot Topics in Hemophilia Nursing

SGLT2 Inhibitors in the Modern Era: Why and Where?

Issues in the Management of Hemophilia: A Best Practice Series

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

CDK4/6 Inhibitors in Practice

Next-Gen Psoriasis Therapies:

Individualizing Factor Replacement Therapy for Patients With Hemophilia.

Issues in the Management of Hemophilia: A Best Practice Series

Gene Therapy: Past, Present, and Future

Exploring Personalized Prophylaxis in Hemophilia A

Immunotherapy for cSCC

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Personalized Therapy in Relapsed or Refractory CLL

Personalizing Management in the Care of Patients With Advanced Sarcoma

Multidisciplinary Approaches to Managing Hemophilia

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.

IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?

Extended Half-life Factor Products in the Management of Hemophilia

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

What's New in PAH?.

The Changing Field of Melanoma: Ipilimumab.

Are We Making Progress in the Management of Huntington Disease?

Oral Prostacyclin Pathway Agents in PAH

Optimizing Joint Health in Hemophilia

Practical Guidance on the Management of Pan-Negative NSCLC

Add-On Therapy to Insulin in T1DM Management

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Challenges in LA SCCHN.

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

First-Line FCR: Effect of del(17p) on PFS and OS

Assessing the Burden of Hyperkalemia

Program Goal. Program Goal Disclaimer Overview.

Selecting Treatment Approaches in Hemophilia

Checkpoint Inhibitors in First-Line Advanced NSCLC

Transitioning Therapy in PAH: Practical Strategies and Considerations

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Assessing the Burden of Hyperkalemia

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?

Real-World Evidence.

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Immune Checkpoint Inhibitors in Lung Cancer

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Examining the Role of Pharmacokinetics in Hemophilia

RAASi Enabling in the Modern Era

Navigating the Journey

Presentation transcript:

Tailoring Hemophilia Prophylaxis Therapy

Program Goal

Overview

Case 1: A Newly Diagnosed Patient With Severe Hemophilia A

Case 1 Presentation (cont)

Would You Consider Prophylaxis With Prolonged Half-life FVIII in This Patient?

Examples of Prolonged Half-life Factor Products

Entering Infants Into Clinical Trials

Potential Benefits of Prolonged Half-life Factor Productsa-c

Case 2: An Older Man With Severe Hemophilia B

Case 2 Presentation (cont)

Case 2 Presentation (cont)

Considerations Regarding Use of Prolonged Half-life Factor Products in Older Patients

Considerations Regarding Use of Prolonged Half-life Factor Products in Older Patients (cont)

Additional Considerations Regarding Use of Prolonged Half-life Products

Additional Considerations Regarding Use of Prolonged Half-life Products (cont)

Case 3: Inhibitor Development in a Patient With Severe Hemophilia

Options for Inhibitor Development in a Patient With Hemophilia B

Concluding Comments

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)